11-Chloroasimilobine, also known as 1-methoxy-2-hydroxy-11-chloronoraporphine, is a serotonin 5-HT2C receptor agonist of the noraporphine family. It is a synthetic compound and is the racemic 11-chloro derivative of the aporphine alkaloid asimilobine.
The drug acts as a highly selective Gq-preferring biased agonist of the serotonin 5-HT2C receptor. Its () values were 36nM (102%) for Gq signaling and 437nM (62%) for β-arrestin2 recruitment. 11-Chloroasimilobine was inactive as an agonist of the serotonin 5-HT2A and 5-HT2B receptors at concentrations of up to 30,000nM. It was also selective for the serotonin 5-HT2C receptor over a panel of other targets. The drug has been found to reverse the hyperlocomotion induced by dizocilpine (MK801) and phencyclidine (PCP) in rodents. The pharmacokinetics of 11-chloroasimilobine have been studied.
The chemical synthesis of the compound has been described.
11-Chloroasimilobine was described in the scientific literature by Wangzhi Qin and colleagues in 2025. It had previously been patented in 2022.
See also Serotonin 5-HT2C receptor agonist Aporphine alkaloids MQ02-439 Asimilobine Glaucine Nuciferine
References